| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.06 | 0.00 (0.00%) | 0.0334 - 0.2314 | 500.0 (Below Avg) |
Market data as of 10:52AM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 0.06 |
|---|---|
| Previous Close | 0.06 |
| Day's Range | 0.06 - 0.06 |
| Market Cap | 6.4M |
| Avg Volume (10 Day) | 41.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.21 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Fail |
CEO of Immune Pharmaceuticals to Present at BioEquity Europe 2013
Business Wire - Wednesday 05/22/2013 12:01 AM ET
EpiCept Reports First Quarter 2013 Operating and Financial Results
Business Wire - Monday 05/20/2013 12:01 AM ET
| EPCT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 26.64 |
| Company | Last | Change |
|---|---|---|
| Echo Therapeutics Inc | 0.58 | +5.45% |
| Tranzyme Inc | 0.61 | +3.79% |
| Novogen Ltd | 3.88 | -1.77% |
| Aoxing Pharmaceutical Company Inc | 0.22 | 0.00% |
| China Pharma Holdings Inc | 0.24 | +11.79% |
Data is delayed by at least 15 min.